#+HashtagPLUS
In

Menu

Post image 1
Post image 2
Post image 3
Post image 4
Post image 5
Post image 6
Post image 7
Post image 8
Post image 9
Post image 10
Post image 11
Post image 12
Post image 13
Post image 14
Post image 15
Post image 16
Post image 17
Post image 18
Post image 19
Post image 20
Post image 21
Post image 22
Post image 23
Post image 24
Post image 25
Post image 26
Post image 27
Post image 28
Post image 29
Post image 30
Post image 31
Post image 32
1 / 32
0

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

The Japan Times·Jessica Speed·20 days ago
#7hDbuGao
#mhlw#drugs#medicine#parkinsonsdisease#sumitomopharma#cells
Reading 0:00
15s threshold
IPS cells cultured by Sumitomo Pharma

IPS cells cultured by Sumitomo Pharma | Sumitomo Pharma / via JIJI

An advisory panel to the health minister on Wednesday approved Sumitomo Pharma’s Parkinson’s disease treatment Amchepry, which costs ¥55.3 million ($350,600) per patient, to be covered under the national healthcare program.

The approval marks the first commercialized medical product in the world derived from iPS cells, which are created by reprogramming adult cells such as blood or skin cells into a versatile state capable of developing into different tissue types.

Insurance coverage will begin May 20, with treatment expected to be available this fall, according to media reports.

In a time of both misinformation and too much information,
quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

Read More